Ono Pharmaceuticals and Merck Serono entered two agreements covering the former's ONO-4641, a midstage oral compound for multiple sclerosis, and the latter's Stimuvax, a late-stage immunotherapy for cancer. The first deal gives Merck Serono worldwide rights excluding Taiwan, South Korea and Japan to ONO-4641 for $18.75 million upfront plus milestone fees. For the second contract, Ono will pay Merck Serono about $6.7 million upfront for Japanese co-development and co-commercialization rights to Stimuvax.

Related Summaries